VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | Pembrolizumab as adjuvant therapy for TNBC

Abirami Sivapiragasam, MD, Upstate Medical University, Syracuse, NY, discusses an investigation into pembrolizumab in as adjuvant therapy for triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter